Literature DB >> 20032777

NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.

Shylet Chengedza1, Doris Mangiaracina Benbrook.   

Abstract

Treatment of cancer with tumor necrosis factor-alpha (TNF-alpha) is hindered by resistance and toxicity. The flexible heteroarotinoid, SHetA2, sensitizes resistant ovarian cancer cells to TNF-alpha-induced extrinsic apoptosis, and also induces intrinsic apoptosis as a single agent. This study tested the hypothesis that nuclear factor-kappaB (NF-kappaB) is involved in SHetA2-regulated intrinsic and extrinsic apoptosis. SHetA2 inhibited basal and TNF-alpha-induced or hydrogen peroxide-induced NF-kappaB activity through counter-regulation of upstream kinase (IkappaB kinase) activity, inhibitor protein (IkappaB-alpha) phosphorylation, and p-65 NF-kappaB subunit nuclear translocation, but independently of reactive oxygen species generation. Ectopic over-expression of p-65, or treatment with TNF-alpha receptor 1 (TNFR1) small interfering RNA or a caspase-8 inhibitor, each attenuated synergistic apoptosis by SHetA2 and TNF-alpha, but did not affect intrinsic apoptosis caused by SHetA2. In conclusion, NF-kappaB repression is involved in SHetA2 circumvention of resistance to TNF-alpha-induced extrinsic apoptosis, but not in SHetA2 induction of intrinsic apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20032777      PMCID: PMC2902153          DOI: 10.1097/CAD.0b013e3283350e43

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  38 in total

1.  Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase.

Authors:  J Zhang; G Johnston; B Stebler; E T Keller
Journal:  Antioxid Redox Signal       Date:  2001-06       Impact factor: 8.401

2.  Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria.

Authors:  Tongzu Liu; Bethany Hannafon; Lance Gill; William Kelly; Doris Benbrook
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

3.  TNF-alpha activates at least two apoptotic signaling cascades.

Authors:  C Sidoti-de Fraisse; V Rincheval; Y Risler; B Mignotte; J L Vayssière
Journal:  Oncogene       Date:  1998-10-01       Impact factor: 9.867

4.  Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo.

Authors:  Tashanna Myers; Shylet Chengedza; Stan Lightfoot; Yanfang Pan; Daynelle Dedmond; Lauren Cole; Yuhong Tang; Doris M Benbrook
Journal:  Invest New Drugs       Date:  2008-09-18       Impact factor: 3.850

5.  Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells.

Authors:  Shengquan Liu; Chad W Brown; K Darrell Berlin; Aridam Dhar; Suresh Guruswamy; David Brown; Ginger J Gardner; Michael J Birrer; Doris M Benbrook
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

6.  Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.

Authors:  Chioniso Patience Masamha; Doris Mangiaracina Benbrook
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

7.  Promyelocytic leukemia protein sensitizes tumor necrosis factor alpha-induced apoptosis by inhibiting the NF-kappaB survival pathway.

Authors:  Wen-Shu Wu; Zhi-Xiang Xu; Walter N Hittelman; Paolo Salomoni; Pier Paolo Pandolfi; Kun-Sang Chang
Journal:  J Biol Chem       Date:  2003-01-22       Impact factor: 5.157

8.  Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry.

Authors:  Zhongfa Liu; Yilong Zhang; Yousheng Frank Hua; Joseph M Covey; Doris M Benbrook; Kenneth K Chan
Journal:  Rapid Commun Mass Spectrom       Date:  2008-11       Impact factor: 2.419

9.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells.

Authors:  W Wang; J L Abbruzzese; D B Evans; L Larry; K R Cleary; P J Chiao
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

Review 10.  TNF-alpha in promotion and progression of cancer.

Authors:  Frances Balkwill
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

View more
  9 in total

Review 1.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

2.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

3.  Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.

Authors:  Doris Mangiaracina Benbrook; Suresh Guruswamy; Yuhong Wang; Zhongjie Sun; Altaf Mohammed; Yuting Zhang; Qian Li; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2013-07-12

4.  SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Authors:  Doris Mangiaracina Benbrook; Baskar Nammalwar; Andrew Long; Hiroyuki Matsumoto; Anil Singh; Richard A Bunce; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2013-11-20       Impact factor: 3.850

5.  Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study.

Authors:  Ankur Sharma; Elangovan Thavathiru; Doris Mangiaracina Benbrook; Sukyung Woo
Journal:  J Pharm Technol Drug Res       Date:  2017

6.  Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib.

Authors:  Amy L Kennedy; Rajani Rai; Zitha Redempta Isingizwe; Yan Daniel Zhao; Stanley A Lightfoot; Doris M Benbrook
Journal:  Cancers (Basel)       Date:  2020-05-17       Impact factor: 6.639

Review 7.  SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.

Authors:  Doris Mangiaracina Benbrook
Journal:  Front Cell Dev Biol       Date:  2022-02-23

8.  Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2.

Authors:  Rajani Rai; Vishal Chandra; Amy L Kennedy; Rosemary E Zuna; Doris Mangiaracina Benbrook
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

9.  Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Authors:  Doris M Benbrook; Naveena B Janakiram; Vishal Chandra; Gopal Pathuri; Venkateshwar Madka; Nicole C Stratton; Chioniso P Masamha; Cassadie N Farnsworth; Lucila Garcia-Contreras; Manolya Kukut Hatipoglu; Stan Lighfoot; Chinthalapally V Rao
Journal:  Invest New Drugs       Date:  2017-12-22       Impact factor: 3.850

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.